Previous 10 | Next 10 |
Gossamer Bio Inc ( NASDAQ: GOSS ) is in the green on Thursday after a Goldman Sachs analyst said the stock is ready for another huge move to the upside. Gossamer Bio stock could rally to $22 On Thursday, Paul Choi assumed coverage of this “under the radar” biop...
Summary Today, we look back in on a small biotech company called Gossamer Bio. The company's primary drug candidate is approaching a key trial milestone and analyst firms are currently sanguine on Gossamer's long-term prospects. An investment analysis follows in the paragraphs...
Wedbush research on Monday initiated U.S. clinical-stage biotech Gossamer Bio ( NASDAQ: GOSS ) with an outperform rating, as it expects positive data from an ongoing mid-stage trial of the company's lead drug candidate. San Diego, Calif-based GOSS is evaluating an inhibitor,...
Gossamer Bio press release ( NASDAQ: GOSS ): Q2 GAAP EPS of -$0.74 misses by $0.04 . Cash, cash equivalents and marketable securities as of June 30, 2022, were $222.2 million. For further details see: Gossamer Bio GAAP EPS of -$0.74 misses by $0.04
- Seralutinib Phase 2 TORREY Study on track for topline readout in second half of November or first half of December - - CNS-penetrant GB5121 doses first patient in Phase 1b/2 STAR CNS Study in PCNSL and other rare CNS malignancies - - $342 million in cash, cash equiva...
The recent stock rally has made some crowded shorts more squeezable, according to S3 Partners' Ihor Dusaniswky. Dusaniswky created a ranking of the most crowded shorts based on factors like total short dollars at risk, short interest as a true percentage of a company's tradable floa...
3 Methods for Finding Hot Penny Stocks Right Now When it comes to finding penny stocks to buy, there are hundreds of ways to go about it. The most important thing is to have a system in place that you’re comfortable with and that has been proven to work. Because penny stocks ...
Gainers: Canoo ( GOEV ) +28% . Kaspien Holdings ( KSPN ) +18% . Clever Leaves Holdings ( CLVR ) +20% . Yatsen Holding ( YSG ) +17% . Lucira Health ( LHDX ) +17% . Revelation Biosciences ( REVB ) +16% . Kopin Corpo...
Gainers: Biomerica ( BMRA ) +23% . Clene ( CLNN ) +22% . Gossamer Bio ( GOSS ) +11% . Revelation Biosciences ( REVB ) +10% . Nutriband ( NTRB ) +7% . Losers: ContraFect ( CFRX ) -81% . Novavax ( NVAX ) -1...
Gainers: XORTX Therapeutics ( XRTX ) +39% . Gossamer Bio ( GOSS ) +24% . Rhythm Pharmaceuticals ( RYTM ) +23% . Apollo Endosurgery ( APEN ) +18% . Tyra Biosciences ( TYRA ) +15% . Losers: Humanigen ( HGEN ) -80% . Atara Biotherap...
News, Short Squeeze, Breakout and More Instantly...
2024-06-24 17:15:03 ET Oppenheimer analyst issues OUTPERFORM recommendation for GOSS on June 24, 2024 04:04PM ET. The previous analyst recommendation was Buy. GOSS was trading at $0.8261 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cur...
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), will present up...
- Transformative Development and Co-Commercialization Collaboration with Chiesi - - Ongoing PROSERA Phase 3 Study in PAH Expected to Readout in Q4 2025 - - Registrational Phase 3 in PH-ILD Expected to Commence in Mid-2025 - - TORREY Phase 2 PAH Results Published in Lancet ...